Answers are grounded in this paper and cite their sources.
Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: